Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
Public ClinicalTrials.gov record NCT04692688. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized, Placebo-Controlled, Double-Masked Study of the Safety and Efficacy of Orally Administered APX3330 in Subjects With Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy and Mild Proliferative Diabetic Retinopathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
Study identification
- NCT ID
- NCT04692688
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 103 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 8, 2021 (Actual)
- Primary completion
- Jan 25, 2023 (Actual)
- Completion
- Jan 25, 2023 (Actual)
- Last update posted
- Jun 8, 2026
2021 – 2023
United States locations
- U.S. sites
- 24
- U.S. states
- 13
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Site 9 | Phoenix | Arizona | 85014 | — |
| Clinical Site 8 | Bakersfield | California | 93309 | — |
| Clinical Site 5 | Beverly Hills | California | 91607 | — |
| Clinical Site 11 | Palm Desert | California | 92260 | — |
| Clinical Site 2 | Sacramento | California | 95825 | — |
| Clinical Site 24 | Walnut Creek | California | 94598 | — |
| Clinical Site 19 | Miami | Florida | 33143 | — |
| Clinical Site 7 | Winter Haven | Florida | 33880 | — |
| Clinical Site 6 | Carmel | Indiana | 46290 | — |
| Clinical Site 14 | Hagerstown | Maryland | 21740 | — |
| Clinical Site 22 | Springfield | Massachusetts | 01107 | — |
| Clinical Site 17 | Grand Blanc | Michigan | 48439 | — |
| Clinical Site 12 | Albuquerque | New Mexico | 87113 | — |
| Clinical Site 15 | Shirley | New York | 11967 | — |
| Clinical Site 20 | Charlotte | North Carolina | 28210 | — |
| Clinical Site 1 | Rapid City | South Dakota | 57701 | — |
| Clinical Site 18 | Austin | Texas | 78705 | — |
| Clinical Site 16 | Bellaire | Texas | 77030 | — |
| Clinical Site 10 | Fort Worth | Texas | 76104 | — |
| Clinical Site 4 | McAllen | Texas | 78550 | — |
| Clinical Site 3 | San Antonio | Texas | 78240 | — |
| Clinical Site 23 | San Antonio | Texas | 78624 | — |
| Clinical Site 13 | Southlake | Texas | 76092 | — |
| Clinical Site 21 | Ogden | Utah | 84010 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04692688, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04692688 live on ClinicalTrials.gov.